Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

BACKGROUND: Selinexor (KPT-330) is an oral agent that has been shown to inhibit the nuclear exporter XPO1. Given the pressing need for novel therapies for triple-negative breast cancer (TNBC), we sought to determine the antitumor effects of selinexor in vitro and in vivo. METHODS: Twenty-six breast...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Arango, Natalia Paez, Yuca, Erkan, Zhao, Ming, Evans, Kurt W., Scott, Stephen, Kim, Charissa, Gonzalez-Angulo, Ana Maria, Janku, Filip, Ueno, Naoto T., Tripathy, Debu, Akcakanat, Argun, Naing, Aung, Meric-Bernstam, Funda
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5557476/
https://ncbi.nlm.nih.gov/pubmed/28810913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-017-0878-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados